From foresight to investability: what Europe’s 25 technology signals tell investors

The European Innovation Council keeps doing the same useful thing: naming technologies before the market has fully caught up. Its Tech Report 2026 puts 25 of them on the table, from AI agents that can cope with messy real-world settings to robots that service satellites and MRI machines light enough to roll to a bed. These are not forecasts dressed up as certainties. They’re signals — early hints that something might matter later.

Zubr Capital looked at those 25 signals through an investor’s lens. The question was simple enough: which ones have already produced European companies and private money? The analysts checked Q2 2026 financing, plus debt, grants and other public funding, to see where one-off bets were becoming repeated patterns. On that test, embodied AI pulled away from the pack.

Five separate private rounds in the quarter backed European companies tied to that broad shift. That made embodied AI the clearest example of a signal moving past isolated interest and into something investors can actually underwrite. The list ran across stages too: All3 raised $25 million in seed funding, THEKER raised €73 million at Series A, Smart Robotics raised €10 million at Series A, Sereact raised €93 million at Series B, and NEURA Robotics closed a Series C of up to €1.2 billion.

There’s a reason that category is moving. Manufacturers and logistics firms already spend heavily on automation, and they already know where ordinary robots run out of road. Predictable environments are easy. Variable ones are the problem. Embodied AI is trying to push automation into those messier jobs, which makes the commercial case much easier to see than a pure science project.

THEKER shows how that can work in practice. The Barcelona company tested its technology inside Inditex’s operations, and Inditex then invested. When the customer and the investor are the same company, the signal is loud: someone inside the business thinks the technology is worth both trying and backing. And that is what investors want — not just a clever demo, but a route to a real budget.

The report also found 16 other signals with at least one European company and at least one private investment. In Q2 2026, four of those drew fresh capital: Ubotica raised $11 million for satellite edge computing, Mbiomics added €12 million for a microbiome therapy for cancer patients, Imperagen raised £5 million for computational protein design, and SonoMind raised €20 million for focused ultrasound treatment for depression. They are all at different levels of maturity, which is the point. There is no single moment when private money arrives.

Then there are the eight signals with no qualifying private investment at all. Microbial biomining has a European company built around it, but no verified private bet. The rest are even earlier, with the idea visible but the company still missing. Biohybrid microrobots can point to a future in drug delivery, but they are only now moving toward preclinical use. Spin caloritronics, passive cooling and gravity-based energy storage all suggest interesting uses, yet the product and the buyer are still unclear. That is where foresight stops and investability begins.